- 1 Antibiotic Resistance related Mortality, Length of Hospital Stay, and Disability-Adjusted Life
- 2 Years at select Tertiary Hospitals in Uganda: A retrospective study
- 3 **Authors:** Jonathan Mayito¹, Flavia Dhikusooka¹, Daniel Kibombo¹, Andrew Busuge¹, Alex Andema²,
- 4 Alfred Yayi², Stephen Obbo², Richard Walwema¹, Francis Kakooza¹
- 5 1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala P.O. Box
- 6 22418, Uganda
- 7 2. Arua, Jinja, Mbale Regional Referral Hospitals, Ministry of Health, Kampala P.O. Box 7272,
- 8 Uganda

- 10 Abstract
- 11 Background
- Antimicrobial Resistance (AMR) is a major global health threat but its burden has not been extensively
- 13 described in Uganda. We aimed to investigate the antibiotic resistance related mortality, length of
- 14 hospital stays (LOS) and Disability Adjusted Life Years (DALYs).
- 15 Methods
- 16 This was a retrospective study of clinical records of patients with infectious syndromes admitted at
- 17 Arua, Jinja and Mbale regional referral hospitals between October 2022 and September 2023. Data was
- abstracted from clinical records and analyzed to derive the mortality, LOS, DALYs, and factors
- 19 associated with AMR and mortality using the modified Poisson regression model.
- 20 Results:
- 21 Of the 291 participants included in the analysis, 56.6% were males, 10% were living with HIV, and
- 22 their median age was 35 years (IQR: 21-56). The most common infectious syndromes were sepsis
- 23 (43.6%) and diarrhea (9.6%). The prevalence of antibiotic-resistant infections (ARI) was 29.6%, while
- 24 that for multi-drug resistant infections (MDRI) was 17.9%. Patients at Jinja and Mbale RRHs exhibited
- 25 and the present the porternous research that has excepted by edgrading and should not be fully filling the processing by edgrading and should not be fully filling the processing by edgrading and should not be fully filling the processing by edgrading the processing by edgrading the processing by edgrading the processing by edgrading the processing the processing by edgrading the processing the processing

to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 30.8% of the ARI related mortality was due to MDR infections. Most deaths were due to sepsis (42.3%), followed by pneumonia (15.4%) and meningitis (6.2%). Participants with comorbidities had higher risk of mortality due to ARI (45% vs. 31% for those without comorbidities). Among Gram-negative bacteria, *Escherichia coli* and *Klebsiella* spp contributed most to mortality, while among Gram-positives, *Staphylococcus aureus* and *Enterobacter* spp contributed equally. Patients with ARI's LOS was 1.2 times higher than that for those without ARI while a longer LOS was associated with a 21% higher ARI risk but a 24% decline in risk of death. ARI was associated with higher DALYs, 235.4, compared to 147.0 for non-ARI.

Conclusion

26

27

28

29

30

31

32

33

34

40

41

42

43

44

45

46

47

48

49

50

51

- 35 The study revealed a high burden of AMR in Uganda, including a high prevalence of MDR and
- associated mortality, particularly among patients with comorbidities. This indicates an urgent need for
- 37 stewardship and infection prevention strategies to control the AMR burden.
- 38 **Key words:** Antibiotic resistance, Antimicrobial resistance, AMR related mortality, length of hospital
- 39 stays (LOS) and Disability Adjusted Life Years (DALYs)

Background

The Murry et al 2019 review of the global AMR burden showed a glim picture of accelerated

progression towards the 2015 predictions on the impact of antimicrobial resistance (AMR) on global

health and economic growth (1). Eight years after the prediction that AMR would kill 10 million people

annually by 2050, up to 1.27 million deaths in 2019 were attributed to AMR, surpassing the previous

leading infectious killers including tuberculosis, malaria and Human Immuno-deficiency Virus (HIV)

(1). Over one million of these deaths occurred in the World Health Organization (WHO) African region,

of which majority were in Western Sub-Saharan Africa (2). Worryingly, this burden that

disproportionately fell on the Africa region, coincided with poor AMR surveillance systems in the

region, where the AMR preparedness score was 53% less than the overall Sub-Saharan Africa 2018-

2020 Joint External Evaluation (JEE) score, with many countries lacking National Action Plans (NAP)

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

to address the AMR scourge (3). Antimicrobial resistance has dire consequences including the use of more expensive medicines to treat infections and increased length of hospital stay, which lead to higher healthcare costs and reduced economic productivity [9]. Moreover, resistant infections make undertaking of medical procedures like organ transplants, surgeries and chemotherapy risky (4). To reverse this AMR ascendance and its impact, interventions will need to be based on a wider evidence base of the AMR burden including the clinical outcomes, AMR related economic burden, and disability, which is scarce in the WHO Africa region (1). Despite the growing global attention on AMR, there are substantial limitations in our understanding of the burden, its distribution and the determinants at the population level (5). Currently, majority of the available AMR data describe resistance profiles or mechanism of resistance (6). While this data is important for surveillance and design of treatment protocols, data on AMR burden including clinical outcomes like mortality, disability, length of stay, and their determinant is critical in informing planning, resource mobilization and allocation, policy formulation, and the design of targeted control strategies. Individuals who survive AMR have increased Disability Adjusted Life Years (DALYs) including the years of life lost (YLL) and year lived with disability (YLD). DALYs measure the burden of disease: reduction in life expectancy and diminished quality of life due to the disease (7). Consequently, studying the distribution of DALYs in the community helps to know which communities bear the greatest burden of the disease and to focus interventions on these areas [10]. Cassini et al found that DALYs due to AMR (170 per 100 000) were similar to DALYs due to influenza, tuberculosis, and HIV combined (183 per 100,000) and 25% (127 of 501 DALYs per 100 000) of the burden of health-care-associated infections (HAIs) was due to AMR (8). Up to 67.9% (115 of 170) of the total DALYs were accounted for by four antibiotic-resistant bacteria: third-generation cephalosporin-resistant Escherichia coli, Methicillin resistant Staphylococcus aureus (MRSA), carbapenem-resistant Pseudomonas aeruginosa, and third-generation cephalosporin-resistant Klebsiella pneumoniae (8). The data indicates a high disease burden posed by AMR.

Determination of the AMR related mortality, length of hospital stay, DALYs and the influencing factors would complement the routine surveillance data that has been accrued during the implementation of the 2018 – 2023 NAP (9-11), and offer a comprehensive description of the AMR burden in Uganda. This study therefore provides a more comprehensive description of the Uganda AMR burden in terms of attributable mortality, DALYs and the driving factors. This information is critical in the campaign to have the Uganda government adopt AMR surveillance in its health prioritization, planning, resource mobilization and allocation.

Methodology

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

This was a retrospective study of the AMR related clinical outcomes, length of hospital stay, and associated factors using clinical records of patients with infectious syndromes admitted at Arua, Jinja and Mbale regional referral hospitals (RRH) between October 2022 and September 2023. The records were accessed between 4th and 23rd October 2023. The researchers had access to personal identification information during the data collection but not afterwards. Arua RRH is located in Northwest-Nile region, about 500 km from Uganda's capital, Kampala while Jinja and Mbale RRHs are located about 100 km and 400 km respectively from Kampala in the Eastern part of Uganda. Arua, Jinja, and Mbale RRHs serve catchment populations of 3.5, 4.5, and 4.6 million people respectively (12-14). A data abstraction form was designed, pretested and digitalized using Kobo Toolbox, a free and opensource suite of tools for field data collection. Digitalization included building checks in the abstraction tool to ensure quality of the data collected. A team of clinicians were recruited and trained on the protocol, data abstraction tool, and data collection standard operating procedures before data collection. There was a two-tier review of the data by supervisors and a data manager to ensure completeness of the data collected. Abstraction targeted clinical records of patients with infectious syndromes seen at the participating hospital in the 12 months prior to the study who had culture and sensitivity testing done. The study variables abstracted included referral status, prior antibiotic use, admission date, admission diagnosis, sampling date, comorbidities, antimicrobial susceptibility testing (AST) results,

antibiotics prescribed after culture, treatment outcome, length of hospital stay, and discharge date or date of death, among others.

Sample size consideration

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Sample size was determined using the University of San Francisco online sample size calculator (15), based on a pooled prevalence of MRSA of 49% and 35% among HIV infected and HIV uninfected respectively (7) and calculated odd ratios (OD) and relative risk (RR) of 1.78 and 1.4 respectively (16). A sample size of 388 records was sufficient to determine the study variables at 80% power and 95%

confidence interval (CI).

Statistical analysis

Statistical analysis was conducted in Stata 18. Continuous variables were reported as median and interquartile range (IQR) and categorical variables as proportions in terms of frequencies and percentages. The association between having or not having an Antibiotic Resistant Infections (ARI) and other categorical variables was determined using the Chi-square test of independence while for continuous variables, we utilized the Two-sample Wilcoxon rank-sum (also known as the Mann-Whitney) test. The resulting p-values provided the level of statistical significance for each variable examined. A modified Poisson regression model was fitted on complete cases (N=224) to determine factors associated with ARI, and Prevalence Ratios at 95% CI were obtained. Factors with p-value < 0.2 in the un-adjusted model were selected into the adjusted model. The DALYs were calculated as a sum of YLL and YLD. YLL was determined as number of deaths multiplied by the standard life expectancy at age of death. Since we dealt with individual data, YLL was taken as the average standard life expectancy at age of death. YLD was determined as the number of new cases of a disease multiplied by Disability Weight (DW) multiplied by the average time a person lives with a disease before remission. The length of hospital stay was obtained as the difference between the date of discharge or date of death and date of admission. At all levels of comparisons, a p-value of < 0.05 was taken as statistically significant.

Ethical statement

The study was approved by the Makerere University School of Biomedical Sciences Institutional Review Boards (SBS-2023-329), which granted a waiver of consent to use the clinical records of patients with infectious syndromes at the participating hospitals. The study was also approved by the Uganda National Council of Science and Technology (HS3088ES).

RESULTS

Data was abstracted from 392 records but 101 records for tuberculosis patients were excluded from this analysis because they heavily skewed the data because of the characteristic long length of stay in hospital. In *table 1*, socio-demographic characteristics of 291 participants were examined. Among them, 52.6% were males, 10% were living with HIV, and the median age was 35 years (IQR: 21-56 years).

Table 1: Distributions of demographic characteristics and other factors by antibiotic resistant infections

	Total	Antibiotic Resistant Infection (ARI)		P-value
Characteristic	N(Col%)	No n(Row%)	Yes n(Row%)	
Overall	291	205(70.4%)	86 (29.6%)	
Name of Facility				
Arua Regional Referral Hospital	149(51.2)	127(85.2)	22(14.8)	
Jinja Regional Referral Hospital	60(20.6)	41(68.3)	19(31.7)	
Mbale Regional Referral Hospital	82(28.2)	37(45.1)	45(54.9)	<0.001°
Sex				0.018 ^c
Female	138(47.4)	88(63.8)	50(36.2)	
Male	153(52.6)	117(76.5)	36(23.5)	
Age in years (Median (IQR))	35(21-56)	35(24-56)	35(20-56)	0.852 ^m
Length of Hospital stay in days (Median (IQR)) (N=230)	14(6.0-31.0)	12(6.0-25.5)	25.5(10.0-43.0)	0.001 ^m
Underlying Chronic co-morbid conditions			/	0.152°
No	199(68.38)	135(67.8)	64(32.2)	
Yes	92(31.62)	70(76.1)	22(23.9)	
Patient referral			. ,	0.644c
No	246(84.5)	172(69.9)	74(30.1)	
Yes	45(15.5)	33(73.3)	12(26.7)	
Referral Category (N=44)				0.579 ^f
Lower-level public health facility	32(72.73)	23(71.88)	9(28.12)	
Private health facility	12(27.27)	9(75.00)	3(25.00)	
Died (Treatment Outcome)				0.030°
No	161(55.33)	105(65.2)	56(34.8)	
Yes	130(44.67)	100(76.9)	30(23.1)	
MDRI				<0.001°
No	239(82.1)	205(85.8)	34(14.2)	
Yes	52(17.9)	0(0.0)	52(100.0)	
Prior antibiotic use				0.244 ^f
No	4(1.37)	4(100.0)	0(0.0)	

Yes	287(98.63)	201(70.0)	86(30.0)	
HIV Status				0.501°
No	262(90.0)	183(69.9)	79(30.2)	
Yes	29(10.0)	22(75.9)	7(24.1)	
Clinical Diagnosis at Admission				0.004 ^f
Diarrhea	1(0.3)	1(100.0)	0(0.0)	
Enteric fever	2(0.7)	0(0.0)	2(100.0)	
Meningitis	8(2.8)	8(100.0)	0(0.0)	
Pneumonia	28(9.6)	26(92.9)	2(7.1)	
Sepsis	127(43.6)	84(66.1)	43(33.9)	
UTI	10(3.4)	8(80.0)	2(20.0)	
Other infections	11(39.5)	78(67.8)	37(32.2)	

Col % stands for column percentage, Row % stands for row percentages, IQR stands for inter quantile range, n stands for absolute frequencies, m stands for Mann-Whitney U test, c stands for Pearson Chi-square, and f stands for Fisher's Exact test.

Prevalence of ARI and mortality

The prevalence ARI was 29.6%, while that for multi-drug resistant infections (MDRI) was 17.9%. Overall, mortality due to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 30.8% of the mortality due to ARI, the causative pathogens were multidrug resistant (MDR), *table 2*. The 30-day mortality was 23% compared to 30% for length of stay longer than 30 days, *table 3*. Additionally, 31.6% of participants had underlying comorbid conditions, with HIV (32%) and diabetes (29%) being the most common. Participants with comorbidities had a high mortality (45%) compared to those without comorbidities (31%), *table 4*. Sepsis (43.6%) and diarrhea (9.6%) were the most common infectious syndromes, *table 5*.

Table 2: Mortality due to Antibiotic Resistant Infection

Characteristic (N=86)	Frequency (Col %)
Multi-Drug Resistant Infections (MDRI)	
No	239 (82.10)
Yes	52 (17.90)
Died with ARI (n=86)	
No	56 (65.10)
Yes	30 (34.90)
Died with MDRI (n=52)	
No	36 (69.20)
Yes	16 (30.80)

Table 3: 30-day mortality due ARI

<30 day mortality	
Number of people who died due to ARI with <30 day LOS and ARI	13
Total number of people that died wit ARI	56

% Mortality	23%
>30 day mortality	
Number of people who died due to ARI with >30 day LOS and ARI	17
Total number of people that died wit ARI	56
% Mortality	30%

Table 4: Mortality among those with comorbidities.

Mortality of patients with comorbidities that also had ARI	Frequency (Col %)
Number of patients who had ARI, comorbidities and also died	10
Number of patients that had ARI and comorbidities	22
Mortality due to ARI for patients with comorbidities	45%
Mortality of patients with ARI but had no comorbidities	
Number of patients who had ARI, and died but had no comorbidities	20
Number of patients that had ARI and no comorbidities	64
Mortality due to ARI for patients with comorbidities	31%

Table 5: Clinical Syndromes contributing to death

Clinical Syndrome	Number of Deaths	Percentage
Sepsis	55	42.3
Other infections	43	33.1
Pneumonia	20	15.4
Meningitis	8	6.2
Enteric fever	2	1.5
UTI	2	1.5

Causes of mortality

Most deaths were due to sepsis (42.3%) followed by pneumonia (15.4%) and meningitis (6.2%). Among the Gram-negative bacteria, *Escherichia coli* (7.8%) followed by *Klebsiella* spp (5.5%) contributed most to mortality while among the Gram-positives, *Staphylococcus aureus* and *Enterobacter spp* contributed equally (2.3%) to mortality. Notably, 85.7% of the deaths were due to ESKAPE organisms (*Staphylococcus aureus*, *Klebsiella spp*, *Pseudomonas aeruginosa*, and *Enterobacter* spp), *table 6*.

Table 6: Organisms Contributing to Mortality

Organism isolated	Frequency	Percentage
Citrobacter spp	2	1.56
Escherichia coli	10	7.81
Enterobacter spp	3	2.34
Klebsiella spp	7	5.47

Proteus spp	1	0.78
Pseudomonas spp	1	0.78
Serratia Mascessens	1	0.78
Staphylococcus aureus	3	2.34
No significant growth	100	78.13

Factors associated with ARI

Patients at Jinja RRH exhibited a 2.42 times higher likelihood of ARI compared to those at Arua RRH (95% CI: 1.43-4.12, p=0.001). Similarly, patients at Mbale RRH had a 2.67 times higher likelihood of ARI compared to those at Arua RRH (95% CI: 1.53-4.58, p < 0.001). A log unit increase in length of hospital stay in days was associated with 21% higher risk of ARI (95% CI: (1.15-1.95), p=0.003) while mortality was 1.4 (95% CI: 1.00-1.97) times higher among the ARI but this was not statistically significant, *table* 7. For consideration of length of stay and risk of death, ARI related death ratio was 0.76(95% CI: 0.69-0.85), p<0.001 for the log-transformed length of hospital stay, which indicated that for every one-unit log increase in the length of hospital stay, the death rate decreased by approximately 24% (p<0.001, 95% CI: (0.69-0.85)) for patients, *table* 7.

Table 7: Factors associated with having an antibiotic resistant infection

	Un-adjusted PR (95%		Adjusted PR (95%	
Characteristic	CI)	P-Value	CI)	P-value
Name of facility				
Arua Regional Referral Hospital	Reference		Reference	
Jinja Regional Referral Hospital	2.14(1.25-3.67)	0.005	2.42(1.43-4.12)	0.001
Mbale Regional Referral Hospital	3.72(2.41-5.73)	<0.001	2.65(1.53-4.58)	< 0.001
Sex				
Female	1.54(1.07-2.21)	0.019	1.49(0.96-2.32)	0.075
Male	Reference		Reference	
Length of hospital stay (per unit log increase)	1.36(1.19-1.55)	< 0.001	1.50(1.15-1.95)	0.003
Age (Years)	1.00(0.99-1.01)	0.852	N/A	N/A
Underlying chronic comorbid condition				
No	Reference		Reference	
Yes	0.74(0.49-1.12)	0.164	0.71(0.44-1.13)	0.148
Patient referral				
No	Reference		N/A	N/A
Yes	0.89(0.53-1.49)	0.651	N/A	N/A
Died (Treatment outcome)				
No	Reference		Reference	
Yes	0.66(0.45-0.97)	0.034	1.31(0.88-1.96)	0.189
HIV status				
Negative	Reference		N/A	N/A
Positive	0.80(0.41-1.57)	0.517	N/A	N/A

PR denotes Prevalence Ratios and 95% CI denotes the 95% Confidence interval obtained by fitting a modified Poisson regression model on complete cases (N=224). Factors were selected into the adjusted model if p-value<0.2 at un-adjusted.

Disability adjusted life years (DALYs)

The DALYs for participants with ARI were 235.4, higher than the DALYs for participants without ARI,

147.0.

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Discussion

We provide the first description of bacterial AMR burden including mortality and DALYs in Uganda, a low-income country. Our evaluation reveals a high mortality: 34.9% due to ARI, of which 30.8% was due to MDRI. Moreover, this mortality occurred in presence of a high rate of comorbidities including HIV (32%) and diabetes (29%) and these patients with comorbidities had a higher mortality (45%) compared to those without (31%). Hospital length of stay was 1.2 times higher for patients with ARI compared to those without. A unit increase in length of hospital stay was associated with a 24% reduction in mortality, indicating early mortality before or shortly after AMR has been diagnosed. Most death were due to sepsis, mainly as a result of Gram-negative bacteria, Escherichia coli and Klebsiella spp in particular as well as Staphylococcus aureus and Enterococcus spp among the Gram-positives, with the ESKAPE group accounting for 85.7% of the deaths. All these contributed to higher YLD and DALYs associated with ARI: 189 and 235.4 compared to 101.7 and 147.0 for non-ARI respectively. We noted a high AMR related mortality, with a significant proportion being due to MDRI, which is similar to what has been observed elsewhere. Globally, AMR is surpassing previously leading infectious causes of death: 1.27 million deaths and 4.95 million deaths were related or associated to AMR in 2019, higher than that due to malaria, tuberculosis or HIV/AIDS (1). In the same year, in the WHO African region, 1.05 million deaths and 250,000 deaths were due to and attributed to AMR respectively, the highest mortality rate (23.5 per 100,000) globally (2). Resistant Escherichia coli, among the leading six pathogens causing mortality in the same evaluation, has been associated with an absolute risk of mortality of 58 – 130 per 1000 regardless of the type of resistance (17). South Asia shares with Sub-Saharan Africa the brunt of the AMR burden. Overall, case fatality among neonates

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

admitted to the Neonatal Intensive Care Unit (NICU) in Vietnam was 44.4% with a 31.8% 30-day mortality rate, a 27% increase in odds of fetal outcome and a 2.1 day increase in hospital length of stay (18). A systematic review by Kassim et al reported that AMR increased the mortality due to bloodstream infection by 58% and doubled the risk of ICU admissions (19). The risk of death due to AMR affects both community acquired and hospital acquired (CAI, HAI), where the resistant infections in either type have a higher risk of death (20, 21). AMR has been hitherto an unrecognized infectious cause of death in Uganda. In 2019, up to 7100 deaths were due to AMR while another 30700 deaths were associated with AMR, leaving Uganda with the 165th highest age standardized AMR related mortality among 204 countries (22). Moreover, the AMR related mortality was higher than the previously leading causes of death including tuberculosis, HIV/AIDS and Malaria (22). In this study, the Gram-negative bacteria (Escherichia coli and Klebsiella spp) were responsible for most of the deaths while Staphylococcus aureus and Enterococcus spp contributed most among the Gram-positive. These were among the six leading causes of death in 2019 while others included Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa (1). In the African region, Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus, were the four leading causes of death while third-generation cephalosporin-resistant Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) were the leading pathogen-drug combinations associated with mortality (2). These findings highlight an urgent need to address the AMR challenge, targeting the pathogens responsible for the highest burden in Uganda and the African region at large. Diabetes and HIV/AIDS were highly prevalent among AMR patients, and although presence of comorbidities was not independently associated with AMR, it carried a heightened risk of death. Hyperglycemia impairs the immunity (23), increasing the risk for infectious syndromes like skin and soft tissue infections, urinary tract infections, surgical site infection, and respiratory tract infections among others (24). Relatedly, drug resistant infections are also increased, for instance multidrugresistant Klebsiella pneumoniae and MRSA were more common in hyperglycemic patients compared to normoglycemic patients (25). There has been contrasting evidence on the risk of AMR posed by diabetes: higher AMR was observed in diabetic patients with liver abscess (26) while carbapenem-

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

resistant Klebsiella. pneumoniae was lower among diabetics compared non-diabetics (27). High resistance has been noted in common bacteria isolated from diabetic foot: Staphylococcus aureus against gentamicin (57.96%), and ciprofloxacin (52.45%) and Escherichia coli and Klebsiella Pneumoniae resistance against common antibiotics at more than 50% (28). Overall, AMR is likely to have a higher impact in diabetics due to their heightened risk of infection and frequent exposure to healthcare environment (29). HIV/AIDS was also highly prevalent among patients with AMR in our study. HIV/AIDS weakens the immune system, making individuals prone to infections in addition to the frequent visits to healthcare facilities, which exposes then to infections. HIV/AIDS is associated with high rates of AMR (30): a systematic review showed that people living with HIV (PLWH) were twice as likely to be colonized (31) or infected with MRSA, Streptococcus pneumoniae resistant to penicillin, and third-generation cephalosporins resistant Escherichia coli and Klebsiella pneumoniae (32). Infection prevention measures targeting individuals and hospital or home environment (33), and stewardship practices in the use of antibiotics, in addition to optimized HIV/AIDS care to ensure recovery and sustenance of a robust immune system, are critical measures to protect PLWH from AMR. On the other hand, we had only few cancer patients in the study as the study was done in a general ward setting. Cancer is a recognized immune suppressive condition including the immune suppressive effect of its treatment while surgery or bone marrow related cancer treatments rely on effective infection prevention or treatment (34). Fifty percent (50%) of cancer deaths are due to infections but deaths due to AMR have not been well described (35). However, high rates of AMR especially in ESKAPE organisms, have been reported in cancer patients: Vancomycin Resistant *Enterococcus* (VRE, 80%), fluoroquinolone resistant Escherichia coli (70%), and MRSA (50%), among others (36). Consequences of AMR among cancer patients include increased persistence of bacteremia (25% vs 9.7%), metastatic infection (8% vs 4%), and early case-fatality rates (23% vs 11%) among infections due to resistant ESKAPE pathogens versus other bacteria (36). Moreover, MDR is rampant in cancer patients: 40% in ICU patients including 20% Escherichia coli (94.4% ESBL), 12% Staphylococcus aureus (90.6% MRSA), 12% Enterococcus faecium (18.7% VRE), and 6% Acinetobacter baumannii (36). The high

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

burden of comorbidities and associated risk of AMR and the related adverse outcomes highlight the urgent need for strategies to curtail the threat posed by the comorbidities. Our study's finding that patients with AMR stayed 1.2 times longer in hospital than patients without AMR, is similar to finding by a study in Ghana, where AMR patients stayed 5 days and 8 days longer than patients with susceptible infections and non-infected patients respectively (19, 37). This is far more than what was found in France, where the excess length of stay due to AMR was only 1.6 days, and 2.9 days in Australia (38, 39). This highlights the difference between the first world and low resource settings. In the first world appropriate diagnostics can aid in early identification of AMR and alternative options of treatment are more available. Long stay in hospital is associated with higher consumption of hospital resources, higher expenditure for the patient, loss of economic productivity and risk of mortality. For instance, in the Ghana study, AMR related costs were USD 1300 higher than those due to susceptible infections, with 30% of the costs being due to loss of productivity through presenteeism and absenteeism (37). Relatedly, the average AMR related cost was less in France (USD 1173) (38) while 40% of AMR related costs in Europe and the United States were also due to loss of productivity (40). A systematic review by Kassim et al estimated a direct cost per AMR case of USD 12,000 in low and middle income countries (LMICs) (19). Hospital acquired infections are more commonly MDR, posing an intense challenge to healthcare. Mauldin et al found that hospital costs and length of hospital stay due to resistant Gram-negative HAI were 29.3% and 23.8% higher than those due to susceptible Gram-negative bacteria (41). On the contrary, however, Wonziak et al did not find any significant difference in length of hospital stay between drug resistant and drug susceptible CAI in Australia (20), as did Barassa et al (42) in Spain. Suzuki et al also found negligible additional length of stay (0.8 days) attributable to resistant Escherichia coli and Klebsiella spp compared to the prolonged length of stay already imposed by bacteremia due to the same organisms (43). In our study every unit increase in time in hospital was associated with a 24% reduction in mortality. Much as the effect of AMR on length of hospital stay has been widely studied, its effect on or relation with mortality has not been fully evaluated. The finding of reduced mortality with a unit increase in length of stay may imply

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

early mortality due AMR before appropriate diagnosis is made or before appropriate treatment is instituted, implying that those who survive through the early events have higher chances of survival. By accounting for healthy life years lost due to premature death and years lost living with disabilities, DALYs offer a better estimate of burden of disease (44). We found that the DALYs due ARI (235) were almost two times higher than those due to non-ARI (147). AMR related DALYs in our setting were close but higher than DALYs observed in Japan (195) in 2021 (45) but two and four times higher than those in Switzerland (98) and German (57) respectively in 2023 (46), highlighting that low resource settings bear a significantly higher AMR burden. Moreover, the magnitude of DALYs can be affected by type of pathogen (Staphylococcus aureus, Acinetobacter baumannii, and Streptococcus pneumoniae are associated with higher DALYS), sex (higher in male except in women in the reproductive age groups), and site of infection (blood stream infections and bone and joint infection are associated with higher DALYs) while geographical and socio-demographic differences have also been noted (45, 47, 48). These differences likely result from the effect of these parameters on the components used to calculate YLL and YLD particularly number of deaths, incidence of AMR cases, and disability weights. Availability of diagnostic tests and alternative options of treatment for AMR which affect risk of death or the time one stays with the resistant infection, might also explain the difference between high versus low income settings. We note that the admitting hospital and length of stay in hospital were independently associated with ARI. The three admitting hospitals are located within cities, however, the communities in eastern part of the country are more urbanized than those in the north. Bacterial activity, antibiotic resistant genes, and MDR bacteria in the environment have been noted to increase with urbanization and to differ by level of urbanization, with population size as a key driving factor (49). Conditions in urban centers including; poor housing, poor drainage and poor sanitation; poorly-regulated and private provision of medical services including access to antimicrobials, poor waste management, and increased demand for food-animals associated with inappropriate use of antibiotics as growth-promoters, which drive emergence and transmission drug resistant infection, increase with urbanization (5). Mauldin et al also showed that parameters associated with increased hospital costs and length of stay respectively

included pneumonia diagnosis (43.8% vs. 38.2%), ICU admission (142% vs. 106%), neutropenia (83.5% vs. 70.9%) and organ transplant (115.8% vs. 74%) while patients 12 years or more had a 26.3% lower hospital cost but a 66.8% lower length of stay versus those younger (41). Among patients referred for long term care in Chicago, USA, presence of a feeding tube and polymicrobial infection were associated with ARI while urinary catheter, decubitus ulcer, prior use of antibiotics and previous admission within 30 days of current admission were not (50). On the other hand, MDR Pseudomonas aeruginosa infection was independently association with sex, age, and comorbidities, and correlated with ventilation history and neutropenia (51). On the other hand, cotrimoxazole, amikacin, or imipenem except cefazolin; admission to ICU and prior use of acid-suppressive medication were associated with infection with MDR organisms (52). These factors can be targeted by strategies to control AMR and those to improve patient outcomes. Our study strength lies in it being the first expanded description of AMR burden in Uganda, a resource limited setting, revealing critical data that can inform strategies to control AMR, improve clinical outcomes as well as planning and resource allocation. It was limited in geographical scope as only two regions of Uganda were represented, which may not be representative of other regions in the country. Finally, because of the retrospective design, there was missing data on some of the critical parameters that would have been of interest to evaluate.

Conclusion/recommendation

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

Uganda faces a high AMR burden characterized by a high mortality and a high rate of MDR infections, high DALYs and increased length of hospital stay, in a setting of a high rate of comorbidities including HIV and diabetes. Sepsis, majorly due to resistant Gram-negative bacteria, contributed most to the AMR burden. While these findings can shape the early targeted AMR control strategies, a larger evaluation covering all regions of the country to comprehensively describe the burden is urgently needed.

Author contribution

- Jonathan Mayito, Conceptualization, Investigation, Methodology, Project Administration, Writing –
- 341 Original Draft Preparation
- 342 Flavia Dhikusooka, statistical analysis, Review and Editing
- Daniel Kibombo, Investigation, Methodology, Writing Review & Editing
- 344 Alex Andema, Writing Review & Editing
- 345 Stephen Obbo, Writing Review & Editing
- 346 Alfred Yayi, Writing Review & Editing
- Richard Walwema, Resource, Methodology, Supervision, Writing Review & Editing
- 348 Francis Kakooza, Resources, Methodology, Supervision, Writing Review & Editing
- 349 Conflict of interest
- 350 All authors report no conflict of interest
- 351 Financial disclosure
- 352 This work was funded by the Royal Society of Tropical Medicine and Hygiene (RSTMH) Early Career
- 353 Award in partnership with the National Institute for Health and Care Research (NIHR).
- 354 References
- 355 1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in
- 356 2019: a systematic analysis. Lancet. 2022 Feb;399(10325):629-55.
- 357 2. Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the
- 358 WHO African region in 2019: a cross-country systematic analysis. Lancet. 2023 Dec;12(2):E201-E16.
- 359 3. Elton L, Thomason MJ, tembo J, et al. Antimicrobial resistance preparedness in sub-Saharan
- 360 African countries. BMC. 2020;145(9).
- 361 4. WHO. Antimicrobial resistance. [Internet]. 2021 Nov.
- 362 5. Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS, et al. Antimicrobial
- resistance in human populations: challenges and opportunities. Glob Health Epidemiol Genom. 2017
- 364 May 10:2:e4.
- 365 6. Kivumbi MT, Standley CJ. Efforts to Identify and Combat Antimicrobial Resistance in Uganda:
- 366 A Systematic Review. Trop Med Infect Dis. 2021 May;6(2):86.
- 367 7. Global Health CEA. The DALYs. [Internet].
- 368 8. Cassini A, Högberg LD, Plachouras D. Attributable deaths and disability-adjusted life-years
- 369 caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in
- 370 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56–66.

- 371 9. Nabadda S, Kakooza F, Kiggundu R, et al. Implementation of the World Health Organization
- 372 Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study
- 373 Using National Surveillance Data. JMIR Public Health Surveill. 2021 Oct 7(10)::e29954.
- 374 10. Mugerwa I, Nabadda SN, Midega J, et al. Antimicrobial Resistance Situational Analysis 2019-
- 2020: Design and Performance for Human Health Surveillance in Uganda. Trop Med Infect Dis. 2021
- 376 Sep;6(4):178.
- 377 11. Mayito J, Kibombo D, Olaro, et al. Characterization of Antibiotic Resistance in Select Tertiary
- Hospitals in Uganda: An Evaluation of 2020 to 2023 Routine Surveillance Data. Trop Med Infect Dis
- 379 2024;9(4):77.
- 380 12. Mbale RRH. Mbale Regional Referral Hospital. [Hospital website].
- 381 13. Peaditric Health Intiative. Jinja Regional Referral Hospital. [Internet].
- 382 14. Ministry of Health. Arua Regional Referral Hospital. [Internet].
- 383 15. Francisco UoCS. Sample Size Calculators for designing clinical research. [Internet].
- 384 16. Olaru I D, Acconelli E, Yeung E, et al. The association between antimicrobial resistance and HIV
- infection: a systematic review and meta-analysis. CMI. 2021 Jun;27(6):P846-53.
- 386 17. MacKinnon MC, Sargeant JM, Pearl DL, et al. Evaluation of the health and healthcare system
- 387 burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and
- meta-analysis.9, 200 (2020). . Antimicrob Resist Infect Control 2020;9(200).
- 389 18. Peters L, Olson L, Khu DTK, Linnros S, Le NK, Hanberger H, et al. Multiple antibiotic resistance
- as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive
- 391 care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. PLoS
- 392 ONE 2019;14(5):e0215666.
- 393 19. de Kraker MEA. Understanding the impact of antimicrobial resistance on outcomes of
- bloodstream infections in low- and middle-income countries. PLoS Med. 2023;20(7):e1004262.
- 395 20. Wozniak TM, Dyda A, Lee X. The Increased Length of Hospital Stay and Mortality Associated
- 396 With Community-Associated Infections in Australia. Open Forum Infect Dis. 2022 Mar;9(5):ofac133.
- 397 21. Neubeiser A, Bonsignore M, Tafelski CS, Alefelder C. Mortality attributable to hospital
- acquired infections with multidrug-resistant bacteria in a large group of German hospitals. Journal of
- 399 Infection and Public Health. 2020 Feb;13(2):204-10.
- 400 22. IHME. The burden of antimicrobial resistance (AMR) in Uganda. [Internet]. 2019.
- 401 23. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes
- 402 Care. 2003;26:510–3.
- 403 24. Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections:
- development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020
- 405 Jul;202(5):953-65.
- 406 25. Yi H, Huang J, Guo L, Zhang Q, Qu J, M Z. Increased Antimicrobial Resistance among Sputum
- 407 Pathogens from Patients with Hyperglycemia. Infection and drug resistance. 2020;13.
- 408 26. Tian LT, Yao K, Zhang XY, al. e. Liver abscesses in adult patients with and without diabetes
- 409 mellitus: an analysis of the clinical characteristics, features of the causative pathogens, outcomes and
- 410 predictors of fatality: a report based on a large population, retrospective study in China. Clin Microbiol
- 411 Infect. 2012;18(E314-30).
- 412 27. Tian L, Tan R, Chen Y, al e. Epidemiology of Klebsiella pneumoniae bloodstream infections in
- 413 a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob
- 414 Resist Infect Control. 2016;5:48.
- 415 28. Wada FW, Mekonnen MF, Sawiso ED, et al. Bacterial profile and antimicrobial resistance
- 416 patterns of infected diabetic foot ulcers in sub-Saharan Africa: a systematic review and meta-analysis.
- 417 Sci Rep. 2023;13:14655.
- 418 29. Dunachie S, Chamnan P. The double burden of diabetes and global infection in low and
- 419 middle-income countries. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2019
- 420 Feb;113(2):56-64.

- 421 30. Jemal M, Deress T, Belachew T, Adem Y. Antimicrobial Resistance Patterns of Bacterial Isolates
- 422 from Blood Culture among HIV/AIDS Patients at Felege Hiwot Referral Hospital, Northwest Ethiopia.
- 423 Int J Microbiol. 2020 Oct:8893266.
- 424 31. Henderson HI, Ruegsegger L, Alby K, et al. Antimicrobial-resistant Enterobacterales
- 425 colonization in people with HIV. JAC-Antimicrobial Resistance. 2022 Aug;4(4):dlac082.
- 426 32. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
- 427 between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. Clin
- 428 Microbiol Infect. 2021 Jun;27(6):846-53.
- 429 33. Livesley N. PROTECTING PATIENTS WITH HIV FROM ANTIMICROBIAL RESISTANT ORGANISMS.
- 430 AMR Control. 2016 Jul.
- 431 34. Bratti VF, Wilson BE, Fazelzad R, et al. Scoping review protocol on the impact of antimicrobial
- resistance on cancer management and outcomes. BMJ Open. 2023 Feb;13(2):e068122.
- 433 35. Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res. 2014;161:43-
- 434 89.
- 435 36. AK N, HW B, VG F, et al. Antibiotic resistance in the patient with cancer: Escalating challenges
- 436 and paths forward. CA. 2021 Dec 71(6):488-504.
- 437 37. Otieku E, Fenny AP, Labi A, et al. Attributable Patient Cost of Antimicrobial Resistance: A
- 438 Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. PharmacoEconomics
- 439 Open. 2023;7:257–71.
- 440 38. Touat M, Opatowski M, Brun-Buisson C, et al. A Payer Perspective of the Hospital Inpatient
- 441 Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study. Appl
- 442 Health Econ Health Policy. 2019 Jun;17(3):381-9.
- 443 39. Lee XJ, Stewardson AJ, Worth LJ, Graves N, Wozniak TM. Attributable Length of Stay, Mortality
- Risk, and Costs of Bacterial Health Care-Associated Infections in Australia: A Retrospective Case-cohort
- 445 Study. Clin Infect Dis. 2021 May;72(10):e506-e14.
- 446 40. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted
- phenomenon. Pathogens Glob Health. 2015;109(7):309–18.
- 448 41. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length
- of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative
- 450 bacteria. Antimicrob Agents Chemother. 2010 Jan;54(1):109-15.
- 451 42. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on Morbidity, Mortality, and
- 452 Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms. Clinical Infectious
- 453 Diseases. 2017 Aug;65(4):644-52.
- 454 43. Suzuki H, Perencevich EN, Nair R, Livorsi DJ, Goto M. Excess Length of Acute Inpatient Stay
- 455 Attributable to Acquisition of Hospital-Onset Gram-Negative Bloodstream Infection with and without
- 456 Antibiotic Resistance: A Multistate Model Analysis. Antibiotics. 2020;9(2):96.
- 457 44. WHO. THE GLOBAL HEALTH OBSERVATORY: Explore a world of health data. [Internet].
- 458 45. Tsuzuki S, Koizumi R, Matsunaga N, al. e. Decline in Antimicrobial Consumption and Stagnation
- 459 in Reducing Disease Burden due to Antimicrobial Resistance in Japan. Infect Dis Ther 2023;12:1823–
- 460 34.
- 461 46. Gasser M, Cassini A, Lo Fo Wong D, Gelormini M, Nahrgang SA, Zingg W, et al. Associated
- deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in
- 463 Switzerland, 2010 to 2019. Euro Surveill. 2023 May;28(20):2200532.
- 464 47. Lewandrowski KU, da Silva RCL, Elfar JC, et al. Disability-adjusted life years from bone and joint
- infections associated with antimicrobial resistance: an insight from the 2019 Global Burden of Disease
- 466 Study International Orthopaedics (SICOT). 2024.
- 48. Zhang C, Fu X, Liu Y, Zhao H, G W. Burden of infectious diseases and bacterial antimicrobial
- resistance in China: a systematic analysis for the global burden of disease study 2019. Lancet Reg
- 469 Health West Pac. 2023 Nov;43:100972.
- 470 49. Zhu J, Li R, Yan Y, Cui L. Urbanization drives the succession of antibiotic resistome and
- 471 microbiome in a river watershed. Chemosphere. 2022 Aug;301:134707.

- 472 50. Toubes EK, Singh D, Yin R, et al. Risk Factors for Antibiotic-Resistant Infection and Treatment
- 473 Outcomes among Hospitalized Patients Transferred from Long-Term Care Facilities: Does
- 474 Antimicrobial Choice Make a Difference? Clinical Infectious Diseases. 2003 Mar;36(6):724–30.
- 51. Shbaita S, Abatli S, Sweileh MW, al. e. Antibiotic resistance profiles and associated factors of
- 476 Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing
- 477 country. Antimicrob Resist Infect Control 2023;12:149.

484

- 478 52. Alsehemi AF, Alharbi EA, Alammash BB, et al. Assessment of risk factors associated with
- 479 multidrug-resistant organism infections among patients admitted in a tertiary hospital a
- retrospective study. Saudi Pharmaceutical Journal. 2023 Jun;31(6):1084-93.